Sugerencias
Compartir
Información de la revista
Compartir
Más opciones de artículo
Acceso a texto completo
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial
, H.. Shahbazianb, Heshmatolah Shahbazianc, A.. Zafar Mohtashamid, Azita Zafar Mohtashamie, A.. Ghorbanid, Ali Ghorbanie, M.R.. Abbaspourf, Mohammad Reza Abbaspourg, S.S.. Belladi Musavih, Sayed Seifolah Belladi Musavii, Fatemeh Hayatii, Ghollam Reza Lashkararac
b Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan, Iran,
c Diabetes Research Center, Ahvaz, Khuzestan, Iran,
d Department of Nephrology, Golestan Hospital, Ahvaz, Khuzestan, Iran,
e Department of Nephrology, Golestan Hospital, Ahvaz, Khuzestan, Iran,
f Nanotechnology, Faculty of Pharmacy, Ahvaz, Khuzestan, Iran,
g Faculty of Pharmacy, Nanotechnology, Ahvaz, Khuzestan, Iran,
h Department of Nephrology, Imam Hospital, Ahvaz, Khuzestan, Iran,
i Department of Nephrology, Imam Hospital, Ahvaz, Khuzestan, Iran,

Artículo

This article is available in English

Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial

H. Shahbazian, Heshmatolah Shahbazian, A. Zafar Mohtashami, Azita Zafar Mohtashami, A. Ghorbani, Ali Ghorbani, M.R. Abbaspour, Mohammad Reza Abbaspour, S.S. Belladi Musavi, Sayed Seifolah Belladi Musavi, Fatemeh Hayati, Ghollam Reza Lashkarara
10.3265/Nefrologia.pre2010.Nov.10734
Nefrologia (English Version). 2011;31:58-65
Idiomas
Nefrología